Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

CytomX & Astellas Collaborate To Develop Novel Cancer Therapy

By Zacks Investment ResearchStock MarketsMar 24, 2020 10:13PM ET
CytomX & Astellas Collaborate To Develop Novel Cancer Therapy
By Zacks Investment Research   |  Mar 24, 2020 10:13PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

CytomX Therapeutics, Inc. (NASDAQ:CTMX) and Japan-based Astellas Pharma entered into a strategic collaboration for discovering, developing and commercialization of novel T-cell engaging bispecific antibodies, which target CD3 and tumor cell surface antigens for treating cancer. The companies will use CytomX’s Probody therapeutic technology platform and bispecific formats and CD3 modules for development of treatment targeting solid tumors.

Per the terms of the deal, Astellas will pay CytomX an upfront payment of $80 million in cash. CytomX will also be eligible to receive additional payments of up to $1.6 billion related to future preclinical, clinical and commercial milestones as well as royalties on global net sales on any commercialized product under the deal. CytomX will be responsible for initial research and discovery activities. Following candidate selection for development, Astellas will be responsible for preclinical and clinical development and commercialization activities.

Meanwhile, CytomX has options to co-develop a specified number of targets with Astellas Pharma, which need to be exercised before initiation of first pivotal study on chosen candidates. CytomX will be eligible to receive certain portion of profits from sales of jointly developed drugs in the United States. The company may also elect to co-commercialize the products in the U.S. market.

The deal gives CytomX the opportunity to expand its potentially transformational Probody technology and provides the company with additional financial and strategic flexibility.

So far this year, share of CytomX have declined 21.5% compared with the industry’s decrease of 16.7%.

Apart from Astellas Pharma, CytomX has other collaboration agreements with multiple pharma/biotech companies related to use of its Probody therapeutic technology platform. The company is developing two early- to mid-stage candidates in partnership with Bristol-Myers (NYSE:BMY) in combination with the latter’s PD-1 inhibitor, Opdivo, targeting cancer indication. CytomX is also developing another early-stage candidate in collaboration with AbbVie (NYSE:ABBV) targeting solid tumors. Last year, AbbVie selected a second research target to develop under the collaboration. CytomX also has a collaboration with Amgen (NASDAQ:AMGN) to develop CytomX Probody T-cell engaging bispecific program that targets the EGFR protein in cancerous cell.

CytomX also has two candidates in its internal pipeline. The lead candidate, CX-072, a Probody therapeutic targeting PD-L1, is being developed as monotherapy in five oncology indications including triple negative breast cancer. The company is developing CX-072 in combination with Bristol-Myers’ Yervoy in patients with unresectable or metastatic melanoma whose disease has progressed or relapsed after receiving treatment with a PD-1/PD-L1 immune checkpoint inhibitor. The candidate is also being developed in combination with Roche’s cancer drug, Zelboraf, in patients with V600E BRAF-positive melanoma.

CytomX is developing the second candidate, CX-2009, as monotherapy in a phase II study as a treatment for hormone receptor (ER, PR) positive, HER2 negative breast cancer.

Zacks Rank

CytomX currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report

Amgen Inc. (AMGN): Free Stock Analysis Report

AbbVie Inc. (ABBV): Free Stock Analysis Report

CytomX Therapeutics, Inc. (CTMX): Free Stock Analysis Report

Original post

Zacks Investment Research
CytomX & Astellas Collaborate To Develop Novel Cancer Therapy

Related Articles

CytomX & Astellas Collaborate To Develop Novel Cancer Therapy

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email